Merck "Parallel" R&D: Internal Programs Match External To Limit Uncertainty
Executive Summary
Merck's practice of maintaining an internal research program parallel to any third-party collaboration guarantees an R&D project's survival should the external venture lose its funding, Merck Research Labs President Edward Scolnick, PhD, said.
You may also be interested in...
Tort Reform Likely To Move Up PhRMA Priority List
The continued fallout from the Vioxx withdrawal is likely to make tort reform a higher priority for the Pharmaceutical Research & Manufacturers of America heading into 2005
Tort Reform Likely To Move Up PhRMA Priority List
The continued fallout from the Vioxx withdrawal is likely to make tort reform a higher priority for the Pharmaceutical Research & Manufacturers of America heading into 2005
Merck R&D Labs Heir-Apparent Kim To Head Basic Research, Clinical Science
Merck's external R&D recruiting has produced an heir-apparent to Edward Scolnick, MD, as head of Merck Research Laboratories.